Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review

Mullen, Mary M.; Kuroki, Lindsay M.; Thaker, Premal H.

doi:10.1016/j.ygyno.2018.10.023

Cited by 31 publications

(32 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More specifically, PARP inhibitors (Olaparib) can be introduced as maintenance monotherapy in relapsed disease patients with BRCA mutation. Recently, SOLO-1 trial showed that among 391 patients with newly diagnosed advanced high-grade serous or endometrioid OC, primary peritoneal cancer, or fallopian-tube cancer (or a combination thereof) with a mutation in BRCA1, BRCA2, or both who underwent randomization, the use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced OC and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olaparib than with placebo during a 41 month follow-up period [4,20,21].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC

Iavazzo

Fotiou

Tsiatas

et al. 2020

Pleura and Peritoneum

View full text Add to dashboard Cite

BackgroundThe aim of this survey was to acquire an overview of the current management of ovarian cancer with an emphasis on the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).Methods: An email was sent to Oncologists prior to PSOGI International Symposium on Advanced Ovarian Cancer, Athens 11–13 April 2019. Doctors submitted responses on the relevant website. The self-report survey contained 17 questions.ResultsIn total, 467 Medical Oncologists, Surgical Oncologists or Gynaecologic Oncologists were participated and answered to this survey. The resectability of disease was evaluated by laparoscopy from 48.5% of the participants, while 51.5% answered that they stage their patients pre-surgically with the use of CT or MRI. The preferred first intervention in advanced ovarian cancer patients is the neoadjuvant chemotherapy followed by interval cytoreductive surgery (72%). Regarding the use of HIPEC, almost half of the participants answered that there is role of HIPEC use in ovarian cancer patients undergoing interval debulking surgery, while almost 70% answered positively about the utility of HIPEC use in ovarian cancer recurrence. As for the role of lymphadenectomy in advanced ovarian cancer patients, half of the responders answered negatively. Finally, only 25% of the participants responded that they always check the BRCA status of their ovarian cancer patients, despite the possible differentiation of treatment based on the molecular profiling (80%).ConclusionsThe results of this survey indicate the utility of HIPEC in treatment of ovarian cancer patients and the differences in the overall management of ovarian cancer patients in the current clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

“…For this reason, the 10 years aggressive ultraradical procedures are a common approach of such a lethal disease. Also, several trials are conducted regarding the new treatment options for recurrent OC [4,5].…”

Section: Introductionmentioning

confidence: 99%

Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC

Iavazzo

Fotiou

Tsiatas

et al. 2020

Pleura and Peritoneum

View full text Add to dashboard Cite

show abstract

“…Trebananib is a peptide that suppresses angiogenesis by inhibiting angiopoietin-1 and -2. Moreover, other treatment strategies involve PARP inhibitors (PARPi) which render PARP enzymes no more capable of performing DNA repair processes and ultimately leading to synthetic lethality [11]. These PARP inhibitors include olaparib (AZD2281), niraparib (MK4827), rucaparib (CO338, AGO14699, and PF01367338), veliparib (ABT-888) and talazoparib (BMN 673) [11].…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, other treatment strategies involve PARP inhibitors (PARPi) which render PARP enzymes no more capable of performing DNA repair processes and ultimately leading to synthetic lethality [11]. These PARP inhibitors include olaparib (AZD2281), niraparib (MK4827), rucaparib (CO338, AGO14699, and PF01367338), veliparib (ABT-888) and talazoparib (BMN 673) [11]. However, it should be noted that that PARP inhibitors have mostly been successful and are approved for patients with platinum sensitive ovarian carcinoma rather than resistant disease [12].…”

Section: Introductionmentioning

confidence: 99%

Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities

Hoter

Naim²

2019

Cancers

View full text Add to dashboard Cite

Ovarian cancer is a serious cause of death in gynecological oncology. Delayed diagnosis and poor survival rates associated with late stages of the disease are major obstacles against treatment efforts. Heat shock proteins (HSPs) are stress responsive molecules known to be crucial in many cancer types including ovarian cancer. Clusterin (CLU), a unique chaperone protein with analogous oncogenic criteria to HSPs, has also been proven to confer resistance to anti-cancer drugs. Indeed, these chaperone molecules have been implicated in diagnosis, prognosis, metastasis and aggressiveness of various cancers. However, relative to other cancers, there is limited body of knowledge about the molecular roles of these chaperones in ovarian cancer. In the current review, we shed light on the diverse roles of HSPs as well as related chaperone proteins like CLU in the pathogenesis of ovarian cancer and elucidate their potential as effective drug targets.

show abstract

“…The starting therapy relays on platinum drugs in combination with paclitaxel or doxorubicin. However, approximately 70% relapse due to insurgence of platinum drug resistance [13]. The resistant cancer type shows higher than normal levels of proteins involved in the replication pathways, including h TS, and cross-resistance with anti- h TS drugs [14,15,16] The above-mentioned anti- h TS drugs become ineffective.…”

Section: Introductionmentioning

confidence: 99%

Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth

et al. 2019

View full text Add to dashboard Cite

Thymidylate synthase (TS) is a prominent drug target for different cancer types. However, the prolonged use of its classical inhibitors, substrate analogs that bind at the active site, leads to TS overexpression and drug resistance in the clinic. In the effort to identify anti-TS drugs with new modes of action and able to overcome platinum drug resistance in ovarian cancer, octapeptides with a new allosteric inhibition mechanism were identified as cancer cell growth inhibitors that do not cause TS overexpression. To improve the biological properties, 10 cyclic peptides (cPs) were designed from the lead peptides and synthesized. The cPs were screened for the ability to inhibit recombinant human thymidylate synthase (hTS), and peptide 7 was found to act as an allosteric inhibitor more potent than its parent open-chain peptide [Pro3]LR. In cytotoxicity studies on three human ovarian cancer cell lines, IGROV-1, A2780, and A2780/CP, peptide 5 and two other cPs, including 7, showed IC50 values comparable with those of the reference drug 5-fluorouracil, of the open-chain peptide [d-Gln4]LR, and of another seven prolyl derivatives of the lead peptide LR. These promising results indicate cP 7 as a possible lead compound to be chemically modified with the aim of improving both allosteric TS inhibitory activity and anticancer effectiveness.

show abstract

Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review

Cited by 31 publications

References 66 publications

Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC

Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC

Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities

Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth

Contact Info

Product

Resources

About